cGMP manufacturing services company Pharmaceutics International Inc (Pii) reported on Thursday the receipt of the US FDA 'smarket approval for seven new products plus the commercially availability of six products in 2017 in collaboration with its partners.
According to the company, the seven US FDA approved products include two oral tablets, one oral capsule, one oral solution, one oral suspension and two sterile injectable products.
Currently, the company has multiple additional approvals pending, including a fast-tracked, aseptically pre-filled syringe product. It has launched four new products and relaunched two sterile injectable products to the market during the year along with its partners.
Early last year, the company conducted a cGMP baseline risk assessment and implemented remediation initiatives to enhance its cGMP systems. It has announced successful MHRA and FDA inspections as well as the approval and launch of numerous products, one of which was the first oral solution product.
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial